Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Sep;191(3):985-92.
doi: 10.1016/j.ajog.2004.05.061.

Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy

D Heather Watts  1 , Deborah L Covington, Karen Beckerman, Patricia Garcia, Angela Scheuerle, Kenneth Dominguez, Brenda Ross, Susan Sacks, Scott Chavers, Hugh Tilson
Affiliations

Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy

D Heather Watts et al. Am J Obstet Gynecol. 2004 Sep.

Abstract

Objective: The purpose of this study was to examine teratogenic risk of antiretroviral (ARV) drugs.

Study design: The Antiretroviral Pregnancy Registry (APR) monitors prenatal exposures to ARV drugs and pregnancy outcome through a prospective exposure-registration cohort. Statistical inference uses exact methods for binomial proportions.

Results: Through July 2003, APR has monitored 3583 live births exposed to ARV. Among 1391 first trimester exposures, there were 38 birth defects, prevalence of 2.7% (95% CI 1.9-3.7), not significantly higher than the CDC's population surveillance rate, 3.1 per 100 live births (95% CI 3.1-3.2). For lamivudine, nelfinavir, nevirapine, stavudine, and zidovudine, sufficient numbers of live births (>200) following first-trimester exposures have been monitored to allow detection of a 2-fold increase in risk of birth defects overall; no increases have been detected.

Conclusion: APR data demonstrate no increase in prevalence of birth defects overall or among women exposed to lamivudine, nelfinavir, nevirapine, stavudine, and zidovudine.

PubMed Disclaimer

Publication types